Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Volume 30, Number 11—November 2024
Research

Quantitative SARS-CoV-2 Spike Receptor-Binding Domain and Neutralizing Antibody Titers in Previously Infected Persons, United States, January 2021–February 2022

Anna BratcherComments to Author , Szu-Yu Kao, Kelly Chun, Christos J. Petropoulos, Adi V. Gundlapalli, Jefferson Jones1, and Kristie E.N. Clarke1
Author affiliation: Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA (A. Bratcher); Alan Shawn Feinstein College of Education, University of Rhode Island, Kingston, Rhode Island, USA (S.-Y. Kao); Labcorp Esoterix, Calabasas, California, USA (K. Chun); Labcorp-Monogram Biosciences, South San Francisco, California, USA (C.J. Petropoulos); Centers for Disease Control and Prevention, Atlanta (A.V. Gundlapalli, J. Jones, K.E.N. Clarke)

Main Article

Table

Characteristics of subjects in a study of quantitative SARS-CoV-2 spike receptor-binding domain and neutralizing antibody titers in previously infected persons, United States, January 2021–February 2022*

Characteristics % Total US population, 2021 Anti-N seropositive†, n = 1,015,622 Binding antibody titer available, n = 30,967 Neutralizing and binding antibody titers available, n = 744
Sex
M 49.6 4.2 (41.3) 13,146 (42.5) 317 (42.6)
F
 50.3
 5.9 (58.1)
 17,821 (57.5)
 427 (57.4)
Age group, y
<18 21.9 2.4 (23.6) 8,089 (26.1) 231 (31.0)
18–49 42.0 3.5 (34.5) 8,127 (26.2) 133 (17.8)
50–64 19.1 2.4 (23.6) 7,224 (23.3) 153 (20.5)
>65
 16.9
 1.8 (17.7)
 7,527 (24.3)
 227 (30.5)
Residence
Nonmetro 13.8 1.7 (16.7) 5,767 (18.6) 136 (18.3)
Metro
 86.2
 8.4 (82.7)
 25,200 (81.4)
 608 (81.7)
Variant epoch
Wild-type 2.5 (24.6) 9,049 (29.2) 202 (27.2)
Alpha 3.1 (30.5) 6,868 (22.2) 75 (10.1)
Delta 3.7 (36.4) 10,808 (34.9) 361 (48.5)
Omicron 0.9 (8.9) 4,242 (13.7) 106 (14.2)

*Values are no. (%) except as indicated. Population data are from the US Census Bureau (https://www.census.gov). Anti-N, nucleocapsid antibody. †Values are no. × 105 (%).

Main Article

1These co-senior authors contributed equally to this article.

Page created: September 30, 2024
Page updated: October 17, 2024
Page reviewed: October 17, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external